Article
Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
Cancer research - 1 May 2010
Lazzara Matthew J, Lane Keara, Chan Richard, Jasper Paul J, Yaffe Michael B, Sorger Peter K, Jacks Tyler, Neel Benjamin G, Lauffenburger Douglas A
Abstract excerpt
Most non-small cell lung cancers (NSCLC) display elevated expression of epidermal growth factor receptor (EGFR), but response to EGFR kinase inhibitors is predominantly limited to NSCLC harboring EGFR-activating mutations. These mutations are associated with increased activity of survival pathway...
Topics
- Animals
- Antineoplastic Agents
- Butadienes
- Carcinoma, Non-Small-Cell Lung
- Enzyme Activation
- Enzyme Inhibitors
- ErbB Receptors
- Extracellular Signal-Regulated MAP Kinases
- Gefitinib
- HeLa Cells
- Humans
- Lung Neoplasms
- Mice